Description
High Purity 2-Methoxyestradiol CAS 362-07-2 with Safe Delivery
Description
| Cas: | 362-07-2 | MF: | C19H26O3 |
|---|---|---|---|
| MW: | 302.41 | Boiling Point: | 464.4±45.0 °C(Predicted) |
| Melting Point: | 188-190°C | Density: | 1.178±0.06 G/cm3(Predicted) |
| Storage: | Inert Atmosphere,Room Temperature | ||
| High Light: |
High Purity 2-Methoxyestradiol, 362-07-2 2-Methoxyestradiol |
||
High Purity 2-Methoxyestradiol CAS 362-07-2 with Safe Delivery
Product introduction
| Product name | 2-Methoxyestradiol |
| CAS No. | 362-07-2 |
| MF | C19H26O3 |
| MW | 302.41 |
| Solubility | DMSO: 10 mg/mL |
| Density | 1.178±0.06 g/cm3(Predicted) |
| Boiling Point | 464.4±45.0 °C(Predicted) |
| Melting Point | 188-190°C |
Description:
2-methoxyestradiol (2-methoxyestradiol), 2-methoxyestradiol (2ME2) was first found in the urine of pregnant women, and it was previously believed to be the end product of estradiol metabolism. not much. Laboratory data indicate that 2-methoxyestradiol is a substrate of P450CYP1A2, especially CYP3A4; it is also extensively metabolized by uridine diphosphate glucuronyltransferase (UDP-glucuChemicalbookronosyltransferase). CYP1A2, CYP3A4, and uridine diphosphate glucuronyltransferase are widely present in the duodenum, small intestine, and liver, but these enzymes are less distributed in the large intestine. Therefore, oral 2-methoxyestradiol must be released as far as possible in the large intestine, so that more of the absorbed part can enter the systemic circulation. Therefore, it is very urgent to study to improve the druggability of 2-methoxyestradiol.
Uses:
2-Methoxyestradiol has a variety of anti-cancer activities, including breast cancer, liver cancer, gastric cancer, hematopoietic system tumors, etc., and has a broad-spectrum anti-tumor effect. Foreign countries are actively developing it as a new drug, and it is still in the clinical trial stage and has not yet been approved by the FDA for marketing. Preclinical studies have shown that 2-methyl Chemicalbook oxyestradiol is active orally with very low toxicity. Administration of 2-methoxyestradiol to mice inhibited lung and pancreatic cancer metastasis and caused regression of primary tumors, and no drug resistance was observed after multiple administrations. Phase I clinical trials in patients with early breast cancer also showed that the compound was well tolerated.
